Trials / Conditions / Recurrent Squamous Cell Lung Carcinoma

Recurrent Squamous Cell Lung Carcinoma

12 registered clinical trials studyying Recurrent Squamous Cell Lung Carcinoma.

Status	Trial	Sponsor	Phase
Completed	Lung-MAP S1400K: c-MET Positive NCT03574753	SWOG Cancer Research Network	Phase 2
Completed	Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer NCT03373760	SWOG Cancer Research Network	Phase 2
Completed	Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer NCT03377556	SWOG Cancer Research Network	Phase 2
Active Not Recruiting	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stag NCT02785952	SWOG Cancer Research Network	Phase 3
Withdrawn	Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer NCT02536495	Erin Bertino	Phase 1 / Phase 2
Completed	Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Bioma NCT02785913	SWOG Cancer Research Network	Phase 2
Completed	Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous C NCT02965378	SWOG Cancer Research Network	Phase 2 / Phase 3
Completed	Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Rec NCT02785939	SWOG Cancer Research Network	Phase 2 / Phase 3
Completed	Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Ca NCT02766335	SWOG Cancer Research Network	Phase 2 / Phase 3
Completed	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lu NCT02154490	SWOG Cancer Research Network	—
Terminated	Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in T NCT02926638	SWOG Cancer Research Network	Phase 2 / Phase 3
Terminated	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage NCT00946712	SWOG Cancer Research Network	Phase 3